Detection of intraocular infections relies heavily on molecular diagnostics. A fundamental challenge is that only 100–300 µl of intraocular fluid can be safely obtained at any given time for diagnostic testing. The most widely available molecular diagnostic panel for infections in ophthalmology includes 4 separate pathogen-directed polymerase chain reactions (PCRs): cytomegalovirus (CMV), herpes simplex virus (HSV), varicella zoster virus (VZV), and Toxoplasma gondii. Not surprisingly, more than 50% of all presumed intraocular infections fail to have a pathogen identified.1

Metagenomic deep sequencing has the potential to improve diagnostic yield as it is unbiased and hypothesis-free; it can theoretically detect all pathogens in a clinical sample.2,5 Previously, we demonstrated that unbiased RNA sequencing (RNA-seq) of intraocular fluid detects fungi, parasites, DNA and RNA viruses in uveitis patients.2 One obvious drawback regarding RNA-seq is that optimal RNA sequencing requires proper specimen handling, including either flash-freezing or immediate placement of the specimen on dry ice. Although commercial room-temperature RNA-preservatives may address this issue, practicing ophthalmologists may find these collection techniques impractical in an outpatient setting. For pathogens with DNA genomes, metagenomic DNA sequencing (DNA-seq) can circumvent this challenge, as DNA is more tolerant of ambient temperature. This study compares the performance of DNA-seq with conventional pathogen-directed PCRs to diagnose intraocular infections.

De-identified archived vitreous samples received by the Proctor Foundation for pathogen-directed PCR testing from 2010–2015 were included. Samples were previously boiled and stored at −80°C. A total of 31 pathogen-positive reference samples and 36 pathogen-negative reference samples by Proctor PCRs were randomized and subjected to DNA-seq. The sensitivity and specificity of the Proctor’s pathogen-directed PCRs range from 85%–100% and 98%–100%, respectively. The DNA-seq workflow included the following steps: 50 µl of each vitreous sample was used to isolate DNA using the DNeasy Blood & Tissue Kit (Qiagen, Germantown, MD) per the manufacturer’s recommendations, 5 µl of the extracted DNA was used to prepare libraries using the Nextera XT DNA Library Preparation Kit (Illumina, San Diego, CA) and amplified with 12 PCR cycles, and library size and concentration were determined as described.2 Samples were then sequenced to an average depth of 15 × 10⁶ reads/sample on an Illumina HiSeq 4000 instrument using 125 nucleotide (nt) paired-end sequencing. Sequencing data were analyzed using a rapid computational pipeline developed in-house to classify sequencing reads and identify potential pathogens against the entire National Center for Biotechnology Information (NCBI) nt reference database.2 Any infectious agent that had ≥2 nonoverlapping reads to the reference pathogen genome was considered positive if it met both of the following criteria: (1) It is a pathogen known to be associated with infectious uveitis, and (2) reads from this pathogen were not present in the no-template (water only) control on the same run and library preparation. Discrepant samples were evaluated at the Clinical Laboratory Improvement Amendments (CLIA)-certified Stanford Clinical Microbiology and Clinical Virology laboratories, except for human T-cell leukemia virus type 1 (HTLV-1), which was confirmed at the University of California San Francisco using primers targeting the tax gene1 and subsequent amplicon sequencing (Elim Biopharmaceuticals, Inc, Hayward, CA). Laboratory personnel involved in sample preparation, analysis, and confirmatory testing were masked to the reference PCR results until all analyses were completed.

Of the 31 positive-reference samples tested, 27 samples were identified correctly with DNA-seq (Fig 1A, Table S1, available at www.aaojournal.org). Three samples positive for T. gondii and 1 sample positive for VZV by directed-PCR were not detected by DNA-seq. The positivity of these 4 samples was confirmed by directed real-time PCRs. The cycle threshold for VZV was 28.2, while the cycle thresholds for the 3 T. gondii samples ranged from 27–36.5. The positive agreement between DNA-seq and directed-PCR was 87%.

Thirty-six archived vitreous samples that tested negative by all Proctor pathogen-directed PCRs (CMV, VZV, HSV, and T. gondii) were randomly selected for DNA-seq. Twenty eight of 36 samples yielded no additional pathogen (Fig 1B, Table S1, available at www.aaojournal.org), while 8 samples (22%) resulted in 6 additional pathogens either not detected or not tested with pathogen-directed PCRs. Those organisms included CMV, human herpesvirus 6 (HHV-6), HSV-2, HTLV-1, Klebsiella pneumoniae, and Candida dubliniensis. All of these organisms are known to be associated with infectious uveitis (Fig 1B). The results for HHV-6, HTLV-1, Klebsiella pneumoniae, and Candida dubliniensis were confirmed. Two samples tested positive for HSV-2 and CMV by DNA-seq were not confirmed by directed-PCR. Here, it was unclear if DNA-seq can achieve higher sensitivity for CMV and HSV-2 compared with PCR, or whether these were false-negative results by DNA-seq, as these samples yielded only 2 reads on DNA-seq. It should be noted that DNA-seq detected 100% of all samples that tested positive for CMV and HSV by PCR.

An advantage of metagenomic deep sequencing is the ability to apply sequence information to infer the phenotypic behavior of the identified pathogen. We compared samples in which CMV sequences were adequately recovered for the UL54 and UL97 genes, coding for the DNA polymerase and phosphotransferase respectively, and compared with a CMV antiviral drug resistance database developed at Stanford University.3 Of the 7 samples analyzed, 3 had mutations in UL97 (phosphotransferase) that confer ganciclovir and valganciclovir resistance. Two samples were found to have C592G mutations, and 1 sample had both C592G and L595S mutations (Table S2, available at www.aaojournal.org).

In summary, we showed that metagenomic DNA sequencing was highly concordant with pathogen-directed PCRs, despite non-ideal sample handling conditions (boiled, long-term frozen). The unbiased nature of metagenomic DNA sequencing allowed an expanded scope of pathogen detection, including bacteria, fungal
species, and viruses, resolving 22% of cases that had previously escaped detection by routine pathogen-specific PCRs available to ophthalmologists, while concurrently provide drug resistance information. The number of missed pathogens reported in this study is likely an underestimation, as DNA-seq alone cannot detect RNA viruses (e.g., rubella), although a larger sample size may be more representative. These data suggest a practical diagnostic decision tree whereby samples negative by routine PCR are then advanced to both metagenomic DNA and RNA sequencing. This approach will not only complement the current diagnostic paradigm in ophthalmology but also allow for a more comprehensive characterization of the etiology of infectious uveitis.

THUY DOAN, MD, PHD1,2
NISHA R. ACHARYA, MD, MS1,2
BENJAMIN A. PINSKY, MD, PHD3,4
MALAYA K. SAHOO, PHD3
ERIC D. CHOW, PHD5
NIAZ BANAEI, MD3,4
INDRE BUDVYTIENE, MS, CLS6
VICKY Cevallos, BS1
LINA ZHONG, BS1
ZHAOXIA ZHOU, BS1
THOMAS M. LIETMAN, MD1,2
JOSEPH L. DERISI, PHD5,7

1Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California; 2Department of Ophthalmology, University of California, San Francisco, California; 3Department of Pathology, Stanford University School of Medicine, Stanford, California; 4Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California; 5Department of Biochemistry and Biophysics, University of California, San Francisco, California; 6Stanford Health Care, Stanford, CA; 7Chan Zuckerberg Biohub, San Francisco, California

Financial Disclosures: The authors have no proprietary or commercial interest in any materials discussed in this article.

T.D.: Support -- UCSF Resource Allocation Program for Junior Investigators in Basic and Clinical/Translation Science; Research to Prevent Blindness Career Development Award: National Eye Institute of the National Institutes of Health award number K08EY026986.

J.L.D.: Howard Hughes Medical Institute.

N.A.: Advisory board -- Abbvie and Santen.
The contents of this Report are solely the responsibility of the authors and do not represent the official views of the National Institute of Health or Howard Hughes Medical Institute.


Author Contributions:
Conception and design: Doan, Acharya, Lietman, DeRisi
Analysis and interpretation: Doan, Pinsky, Sahoo, Banaci, Budvytiene, DeRisi
Data collection: Doan, Pinsky, Sahoo, Chow, Banaci, Budvytiene, Zhong, Zhou, Cevallos
Obtained funding: Not applicable
Overall responsibility: Doan, Acharya, Pinsky, Banaci, Lietman, DeRisi
Correspondence:
Joseph L. DeRisi, PhD, Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158. E-mail: joe@derisilab.ucsf.edu.

References